))
The DanGer Shock Trail | EBPOM World Congress 2024
Manage episode 430791031 series 3557633
Content provided by Desiree Chappell. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Desiree Chappell or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
This piece looks at the DanGer Shock Trial which examines the efficacy of the Impella device in reducing mortality in patients with acute myocardial infarction and cardiogenic shock. We explain how the device works, its implantation process, and the significant findings from the trial, including a notable reduction in six-month mortality with a number needed to treat (NNT) of eight. Despite higher rates of bleeding and renal filtration therapy in the Impella group, the trial provides strong evidence supporting its use in high-volume centers with trained personnel, emphasizing the importance of careful patient selection and timely intervention.
Presented by Andy Cumpstey and Joff Lacey with their guest Vasileios Panoulas, an interventional cardiologist at Brompton and Harefield Hospitals and an honorary senior clinical lecturer at Imperial College London.
1883 episoade
Distribuie
